7.3 Bronchial Provocation Testing: Methacholine Challenge, Exercise-Induced Bronchospasm, and EIB Protocols

7.3 Bronchial Provocation Testing: Methacholine Challenge, Exercise-Induced Bronchospasm, and EIB Protocols

Bronchial provocation testing (also known as bronchial challenge or airway reactivity testing) is indicated to evaluate patients who present with clinical symptoms suggestive of asthma—such as chronic cough, wheezing, or exertional dyspnea—but who exhibit normal baseline resting spirometry and non-diagnostic bronchodilator reversibility testing. Bronchial challenges measure Airway Hyperresponsiveness (AHR), characterized by exaggerated bronchoconstriction in response to pharmacological or physical stimuli.

Stimuli are broadly categorized into Direct Challenges (e.g., Methacholine, Histamine) which act directly on airway smooth muscle receptors, and Indirect Challenges (e.g., Exercise, Eucapnic Voluntary Hyperpnea [EVH], Mannitol, Hypertonic Saline) which trigger endogenous inflammatory mediator release (histamine, leukotrienes, prostaglandins) from mast cells, basophils, and airway sensory nerves.

---

Contraindications and Pre-Test Safety Screening

Because bronchial provocation testing deliberately induces airway constriction, rigorous pre-test safety screening is mandatory.

Absolute Contraindications

1. Severe Airflow Limitation: Baseline $FEV_1 < 50% \text{ to } 60%$ of predicted (or absolute $FEV_1 < 1.5\text{ Liters}$ in adults). Inducing further bronchospasm in severely obstructed patients poses life-threatening risks.
2. Recent Cardiovascular Events: Myocardial infarction or cerebrovascular accident (stroke) within the preceding 3 months.
3. Known Vascular Aneurysms: Known aortic, cerebral, or thoracic arterial aneurysm (forced exhalation and bronchospasm increase blood pressure and wall stress).
4. Uncontrolled Systemic Hypertension: Systolic $BP > 200\text{ mmHg}$ or Diastolic $BP > 100\text{ mmHg}$.
5. Recent Intraocular or Thoracic Surgery: Recent eye surgery (cataract removal) or thoracic/abdominal surgery where spikes in intrathoracic/intraocular pressure are hazardous.

Pre-Test Medication Withholding Intervals

To prevent false-negative challenge results, bronchoactive medications and dietary agents must be withheld for specific time windows prior to testing:

---

Methacholine Challenge Testing Protocols

Methacholine chloride is a synthetic analog of acetylcholine that binds directly to post-ganglionic muscarinic ($M_3$) receptors on airway smooth muscle cells, triggering muscle contraction and airway narrowing.

Testing Methodologies: Tidal Breathing vs. Dosimeter

Two standardized administration techniques are endorsed by ATS/ERS guidelines:

1. 2-Minute Tidal Breathing Method (Wright Nebulizer): The patient breathes aerosolized methacholine normally (tidal breathing) from a continuous jet nebulizer for 2.0 minutes per concentration step.
2. 5-Breath Dosimeter Method: A breath-actuated dosimeter delivers aerosolized methacholine only during inspiration. The patient takes 5 deep, slow inspirations (from FRC to TLC with a 2-to-5 second breath-hold at TLC per breath) for each concentration step.

Step-by-Step Methacholine Challenge Sequence

1. Baseline Spirometry: Perform repeatable baseline spirometry. If baseline $FEV_1 < 60%$ predicted, abort the test.
2. Diluent Control Phase: Administer the aerosolized diluent control ($0.9%$ Normal Saline without methacholine). Perform spirometry at 30 seconds and 90 seconds post-inhalation.
   • The highest $FEV_1$ achieved post-diluent serves as the true control baseline for calculating the 20% decline threshold.
   • Control Rule: If the diluent causes a $\ge 20%$ drop in $FEV_1$ relative to initial baseline, the patient is hyperreactive to the saline vehicle or nebulizer maneuver, and the test is terminated.
3. Serial Concentration Administration: Administer increasing concentrations of methacholine in serial doubling (e.g., $0.0625, 0.125, 0.25, 0.5, 1.0, 2.0, 4.0, 8.0, 16.0\text{ mg/mL}$) or quadrupling steps.
4. Post-Dose Spirometry: Perform acceptable $FEV_1$ maneuvers at 30 seconds and 90 seconds following completion of each dose step.
5. Termination Criteria: The challenge sequence continues until:
   • $FEV_1$ decreases by $\ge 20%$ from the post-diluent baseline $FEV_1$, OR
   • The maximum methacholine concentration ($16.0\text{ mg/mL}$ or $25.0\text{ mg/mL}$) is reached without a 20% drop.

---

PC20 and PD20 Calculation and Clinical Interpretation

The primary diagnostic metric derived from a methacholine challenge is the $PC_{20}$ (Provocative Concentration causing a 20% drop in $FEV_1$) or $PD_{20}$ (Provocative Dose).

Calculation of $PC_{20}$ via Log-Linear Interpolation

When the final dose causes an $FEV_1$ drop exceeding 20%, $PC_{20}$ is calculated by logarithmic interpolation between the second-to-last concentration ($C_1$, causing $< 20%$ drop $R_1$) and the final concentration ($C_2$, causing $> 20%$ drop $R_2$):

$PC_{20} = \text{antilog} \left[ \log(C_1) + \frac{(\log(C_2) - \log(C_1)) \times (20 - R_1)}{R_2 - R_1} \right]$

Where:

• $C_1$: Second-to-last methacholine concentration ($mg/mL$).
• $C_2$: Final methacholine concentration ($mg/mL$).
• $R_1$: Percent decline in $FEV_1$ at $C_1$.
• $R_2$: Percent decline in $FEV_1$ at $C_2$.

PD20: The Metric the 2017 ERS Standard Prefers

The 2017 ERS technical standard on bronchial challenge testing shifted the primary reported metric from $PC_{20}$ (a concentration) to $PD_{20}$ — the cumulative dose of methacholine, in micrograms, that produces the 20% fall in $FEV_1$. The reason is practical: $PC_{20}$ is only comparable between laboratories that use the identical nebulizer, output rate, and inhalation protocol, whereas a cumulative delivered dose is device-independent.

• Normal cut-off: a $PD_{20} > 400\ \mu g$ of methacholine is considered normal (no clinically significant airway hyperresponsiveness).
• Conversion caution: $PC_{20}$ and $PD_{20}$ are not interchangeable numbers. A laboratory reporting $PC_{20}$ must document the nebulizer model, output, and protocol for the value to mean anything outside that lab.
• Both appear on exams. NBRC-style items still use the classic $PC_{20}$ categories below, so know both frameworks and the 20% fall threshold they share.

Clinical Categorization of Airway Hyperresponsiveness ($PC_{20}$)

---

Exercise-Induced Bronchospasm (EIB) Testing Protocols

Exercise-Induced Bronchospasm (EIB) is an indirect provocation modality where thermal and osmotic stress (airway cooling and drying caused by high ventilation rates) trigger mast cell degranulation and airway smooth muscle constriction.

Equipment and Environmental Standards

• Exercise Modality: Motorized treadmill or cycle ergometer equipped with continuous 12-lead ECG monitoring and pulse oximetry.
• Inspired Air Conditions: The patient must breathe dry air containing low absolute humidity ($< 10\text{ mg } H_2O\text{/L}$) at a room temperature of $20^\circ\text{C to } 25^\circ\text{C}$ (or cold dry air if evaluating winter athletes).

Workload and Target Ventilation Protocol

1. Baseline Spirometry: Record repeatable pre-exercise baseline $FEV_1$.
2. Rapid Workload Ramp: The exercise workload must ramp up rapidly within the first 2 to 4 minutes to achieve high target ventilation:
   • Heart Rate Target: $80%\text{ to } 90%$ of age-predicted maximum heart rate ($\text{HR}_{\max} = 220 - \text{age}$).
   • Minute Ventilation Target: $\ge 50%\text{ to } 60%$ of Maximum Voluntary Ventilation ($MVV$), where estimated $MVV = FEV_1 \times 35 \text{ or } 40$.
3. Sustained Effort: The patient maintains this high target workload for 6 to 8 minutes.

Post-Exercise Spirometry Schedule and EIB Diagnostic Criteria

• Testing Intervals: Spirometry ($FEV_1$) is measured at 5, 10, 15, 20, and 30 minutes post-exercise. (Bronchoconstriction in EIB typically peaks between 5 and 11 minutes post-exercise and spontaneously resolves within 30 to 60 minutes).
• EIB Diagnostic Threshold: A $\ge 10%\text{ to } 15%$ decline in $FEV_1$ relative to the pre-exercise baseline is diagnostic of positive Exercise-Induced Bronchospasm. $\% \text{ Fall in } FEV_1 = \left( \frac{FEV_{1,\text{baseline}} - FEV_{1,\text{lowest post-exercise}}}{FEV_{1,\text{baseline}}} \right) \times 100$

---

Laboratory Safety and Reversal Protocol

Bronchial provocation procedures carry inherent risks of severe acute bronchospasm. Technologists must strictly follow facility safety mandates:

1. Medical Supervision: A qualified physician must be present in the building and immediately reachable during all challenge procedures.
2. Immediate Bronchodilator Reversal: As soon as a challenge test is deemed positive (or upon completion of the maximum dose/exercise protocol), the technologist must immediately administer an inhaled short-acting beta-agonist (Albuterol $2.5\text{ mg}$ via nebulizer or 4 puffs via MDI with spacer).
3. Post-Test Recovery Monitoring: The patient must remain monitored in the laboratory until $FEV_1$ recovers to within $10%$ of their initial baseline.
4. Emergency Resuscitation Readiness: Emergency resuscitation equipment—including supplemental oxygen, airway suction, emergency crash cart with epinephrine and IV bronchodilators—must be physically present inside the testing suite.